Search results
Earnings call: AbbVie projects robust growth and diversified pipeline By Investing.com
Investing.com· 7 hours agoWith a growth platform that accounts for 80% of AbbVie's business, the company saw mid-teens growth...
AbbVie and Gilgamesh Pharmaceuticals Announce Collaboration and Option-to-License Agreement to...
Morningstar· 3 days ago- Collaboration to leverage AbbVie's psychiatry expertise and Gilgamesh's innovative research platform to develop next-generation neuroplastogens for the treatment of psychiatric ...
AbbVie (ABBV) Boosts Neuropsychiatric Portfolio With New Deal
Zacks· 2 days agoFree Report) announced that it has signed a collaboration and option-to-license agreement with New York-based privately held biotech Gilgamesh Pharmaceuticals to research ...
Investors Heavily Search AbbVie Inc. (ABBV): Here is What You Need to Know
Zacks via Yahoo Finance· 2 days agoShares of this drugmaker have returned -0.2% over the past month versus the Zacks S&P 500...
AbbVie shares hold Buy rating with $180 target from TD Cowen By Investing.com
Investing.com· 2 days agoOn Tuesday, TD (TSX:TD) Cowen maintained a positive stance on AbbVie Inc . TD Cowen adjusted its...
What Is the Dividend Payout for AbbVie Stock?
Motley Fool via Yahoo Finance· 3 days agoMany investors hold a stake in AbbVie (NYSE: ABBV) because it offers exposure to the healthcare sector. Industry-based diversification, however, isn't...
3 Magnificent Stocks That Are Passive Income Machines
Motley Fool via Yahoo Finance· 2 days agoThe company is proving to be an innovative...
AbbVie Inc. (NYSE:ABBV) Receives $174.31 Average Target Price from Brokerages
ETF DAILY NEWS· 4 days agoShares of AbbVie Inc. (NYSE:ABBV – Get Free Report) have been given a consensus recommendation of “Moderate Buy” by the thirteen research firms that are presently covering ...
AbbVie joins psychedelic push, inks $2B+ next-gen neuro deal with Gilgamesh
FierceBiotech· 2 days agoAbbVie is wading into the waters of psychedelics, penning a pact with Gilgamesh Pharmaceuticals...
... Post-Rescheduling? Data Analytics Expert Weighs In - Corbus Pharmaceuticals (NASDAQ:CRBP), ...
Benzinga· 2 days agoKey states driving this surge include New York, New Jersey and potentially Florida and Ohio, Bingham...
